Morbimortality consequences of use and misuse of psychoactive medicines in Portugal
Psychoactive medicine misuse in Portugal frequently occurs alongside polysubstance use and is associated with substantial health risks. Public health strategies should prioritize addressing high-risk medicine combinations and therapeutic groups most often found to trigger negative outcomes. This may be achieved by targeted prevention efforts integrated into health system design.
Authors
- Ana Carmona Araújo (ORCID: https://orcid.org/0000-0003-4328-4341)
- Filipa Alves da Costa (ORCID: https://orcid.org/0000-0003-0562-2514)
- João Goulão (ORCID: https://orcid.org/0000-0002-2851-2003)
- José Guerreiro (ORCID: https://orcid.org/0000-0003-0690-4484)
- C. Bulhosa (ORCID: https://orcid.org/0000-0002-6636-5657)
- Ana Paula Martins (ORCID: https://orcid.org/0009-0001-7737-2123)
Institutions
- European Medicines Agency (NL)
- University of Lisbon (PT)
- Rádio e Televisão de Portugal (Portugal) (PT)
- National Laboratory for Civil Engineering (PT)
- Direção Geral do Património Cultural (PT)
Publication Details
- Journal
- British Journal of Clinical Pharmacology
- Published
- 2025-07-19
- DOI
- https://doi.org/10.1002/bcp.70171
- Primary Topic
- Opioid Use Disorder Treatment
- Type
- article
- Field-Weighted Citation Impact
- 0.00